국가: 캐나다
언어: 영어
출처: Health Canada
ISOFLURANE
ABBVIE CORPORATION
N01AB06
ISOFLURANE
99.9%
LIQUID
ISOFLURANE 99.9%
INHALATION
100ML/250ML
Prescription
INHALATION ANESTHETICS
Active ingredient group (AIG) number: 0114368001; AHFS:
CANCELLED POST MARKET
2016-03-21
_ISOFLURANE Product Monograph _ _Page 1 of 28 _ _Date of Revision: December 5, 2017 and Control No.210900 _ PRODUCT MONOGRAPH PR ISOFLURANE USP (isoflurane, USP) volatile liquid (> 99.9% v/v isoflurane) _ _ Inhalation Anesthetic _ _ Date of Preparation: October 5, 1998 Date of Previous Revision: July 18, 2014 AbbVie Corporation Date of Revision: 8401 Trans-Canada Highway February 15, 2018 St-Laurent, Qc, Canada, H4S 1Z1 Submission Control No: 210900 _ISOFLURANE Product Monograph _ _Page 2 of 28 _ _Date of Revision: December 5, 2017 and Control No.210900 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS....................................................................................................9 DRUG INTERACTIONS ..................................................................................................12 DOSAGE AND ADMINISTRATION ..............................................................................14 OVERDOSAGE.................................................................................................................16 ACTION AND CLINICAL PHARMACOLOGY ............................................................16 STORAGE AND STABILITY ..........................................................................................18 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................18 PART II: SCIENTIFIC INFORMATION ...............................................................................19 PHARMACEUTICAL INFORMATION.................... 전체 문서 읽기